Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Trial Profile

Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Vascular disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Proteon Therapeutics
  • Most Recent Events

    • 22 May 2015 According to a Proteon Therapeutics media release, 3-year long-term follow-up data from this study will be presented at the 52nd ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) Congress 2015.
    • 13 Apr 2015 Results presented at 9th Congress of the Vascular Access Society, as per Proteon Therapeutics.
    • 26 Mar 2015 According to a Proteon Therapeutics media release, data from the long-term analysis of this trial was presented at National Kidney Foundation's (NKF) 2015 Spring Clinical Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top